Publications

Found 3 results
Filters: Author is J. Wongpiyabovorn  [Clear All Filters]
2010
C. Ronpirin, Tencomnao, T., and Wongpiyabovorn, J., Association between the -1438A/G polymorphism of the serotonin 2A receptor gene and late-onset psoriasis in a Thai population, vol. 9, pp. 208-214, 2010.
Azmitia EC (2001). Modern views on an ancient chemical: serotonin effects on cell proliferation, maturation, and apoptosis. Brain Res. Bull. 56: 413-424. http://dx.doi.org/10.1016/S0361-9230(01)00614-1   Barth JH and Baker H (1986). Generalized pustular psoriasis precipitated by trazodone in the treatment of depression. Br. J. Dermatol. 115: 629-630. http://dx.doi.org/10.1111/j.1365-2133.1986.tb05776.x   Bray NJ, Buckland PR, Hall H, Owen MJ, et al. (2004). The serotonin-2A receptor gene locus does not contain common polymorphism affecting mRNA levels in adult brain. Mol. Psychiatry 9: 109-114. http://dx.doi.org/10.1038/sj.mp.4001366 PMid:14699448   Collier DA, Arranz MJ, Li T, Mupita D, et al. (1997). Association between 5-HT2A gene promoter polymorphism and anorexia nervosa. Lancet 350: 412. http://dx.doi.org/10.1016/S0140-6736(05)64135-9   Conn PJ, Sanders-Bush E, Hoffman BJ and Hartig PR (1986). A unique serotonin receptor in choroid plexus is linked to phosphatidylinositol turnover. Proc. Natl. Acad. Sci. U. S. A. 83: 4086-4088. http://dx.doi.org/10.1073/pnas.83.11.4086   Griffiths CE and Richards HL (2001). Psychological influences in psoriasis. Clin. Exp. Dermatol. 26: 338-342. http://dx.doi.org/10.1046/j.1365-2230.2001.00834.x PMid:11422186   Guillet-Deniau I, Burnol AF and Girard J (1997). Identification and localization of a skeletal muscle serotonin 5-HT2A receptor coupled to the Jak/STAT pathway. J. Biol. Chem. 272: 14825-14829. http://dx.doi.org/10.1074/jbc.272.23.14825 PMid:9169451   Hoyer D, Hannon JP and Martin GR (2002). Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 71: 533-554. http://dx.doi.org/10.1016/S0091-3057(01)00746-8   Huang J, Li G, Xiang J, Yin D, et al. (2004). Immunohistochemical study of serotonin in lesions of psoriasis. Int. J. Dermatol. 43: 408-411. http://dx.doi.org/10.1111/j.1365-4632.2004.02195.x   Kling A, Seddighzadeh M, Arlestig L, Alfredsson L, et al. (2008). Genetic variations in the serotonin 5-HT2A receptor gene (HTR2A) are associated with rheumatoid arthritis. Ann. Rheum. Dis. 67: 1111-1115. http://dx.doi.org/10.1136/ard.2007.074948 PMid:18006541   León-Ponte M, Ahern GP and O'Connell PJ (2007). Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor. Blood 109: 3139-3146. http://dx.doi.org/10.1182/blood-2006-10-052787   Locala JA (2009). Current concepts in psychodermatology. Curr. Psychiatry Rep. 11: 211-218. http://dx.doi.org/10.1007/s11920-009-0033-x   Lowes MA, Bowcock AM and Krueger JG (2007). Pathogenesis and therapy of psoriasis. Nature 445: 866-873. http://dx.doi.org/10.1038/nature05663 PMid:17314973   Miller SA, Dykes DD and Polesky HF (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16: 1215. http://dx.doi.org/10.1093/nar/16.3.1215   Mössner R, Stiens G, König IR, Schmidt D, et al. (2009). Analysis of a functional serotonin transporter promoter polymorphism in psoriasis vulgaris. Arch. Dermatol. Res. 301: 443-447. http://dx.doi.org/10.1007/s00403-008-0909-3 PMid:18979110   Myers RL, Airey DC, Manier DH, Shelton RC, et al. (2007). Polymorphisms in the regulatory region of the human serotonin 5-HT2A receptor gene (HTR2A) influence gene expression. Biol. Psychiatry 61: 167-173. http://dx.doi.org/10.1016/j.biopsych.2005.12.018   Nedoszytko B, Szczerkowska-Dobosz A, Zablotna M, Glen J, et al. (2007). Associations of promoter region polymorphisms in the tumour necrosis factor-alpha gene and early-onset psoriasis vulgaris in a northern Polish population. Br. J. Dermatol. 157: 165-167. http://dx.doi.org/10.1111/j.1365-2133.2007.07993.x   Nordlind K, Thorslund K, Lonne-Rahm S, Mohabbati S, et al. (2006). Expression of serotonergic receptors in psoriatic skin. Arch. Dermatol. Res. 298: 99-106. http://dx.doi.org/10.1007/s00403-006-0652-6   O'Sullivan RL, Lipper G and Lerner EA (1998). The neuro-immuno-cutaneous-endocrine network: relationship of mind and skin. Arch. Dermatol. 134: 1431-1435. http://dx.doi.org/10.1001/archderm.134.11.1431   Ohara K, Nagai M, Tani K, Tsukamoto T, et al. (1999). Schizophrenia and the serotonin-2A receptor promoter polymorphism. Psychiatry Res. 85: 221-224. http://dx.doi.org/10.1016/S0165-1781(99)00002-5   Ono H, Shirakawa O, Nishiguchi N, Nishimura A, et al. (2001). Serotonin 2A receptor gene polymorphism is not associated with completed suicide. J. Psychiatr. Res. 35: 173-176. http://dx.doi.org/10.1016/S0022-3956(01)00015-2   Osborne SF, Stafford L and Orr KG (2002). Paroxetine-associated psoriasis. Am. J. Psychiatry 159: 2113. http://dx.doi.org/10.1176/appi.ajp.159.12.2113 PMid:12450972   Parsons MJ, D'Souza UM, Arranz MJ, Kerwin RW, et al. (2004). The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol. Psychiatry 56: 406-410. http://dx.doi.org/10.1016/j.biopsych.2004.06.020   Peters BP, Weissman FG and Gill MA (2000). Pathophysiology and treatment of psoriasis. Am. J. Health Syst. Pharm. 57: 645-659.   Reich K, Mossner R, Konig IR, Westphal G, et al. (2002). Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset. J. Invest. Dermatol. 118: 155-163. http://dx.doi.org/10.1046/j.0022-202x.2001.01642.x   Schön MP and Boehncke WH (2005). Psoriasis. N. Engl. J. Med. 352: 1899-1912. http://dx.doi.org/10.1056/NEJMra041320   Serretti A, Drago A and De Ronchi D (2007). HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Curr. Med. Chem. 14: 2053-2069. http://dx.doi.org/10.2174/092986707781368450   Smith AK, Dimulescu I, Falkenberg VR, Narasimhan S, et al. (2008). Genetic evaluation of the serotonergic system in chronic fatigue syndrome. Psychoneuroendocrinology 33: 188-197. http://dx.doi.org/10.1016/j.psyneuen.2007.11.001   Sparkes RS, Lan N, Klisak I, Mohandas T, et al. (1991). Assignment of a serotonin 5HT-2 receptor gene (HTR2) to human chromosome 13q14-q21 and mouse chromosome 14. Genomics 9: 461-465. http://dx.doi.org/10.1016/0888-7543(91)90411-7   Stefulj J, Jernej B, Cicin-Sain L, Rinner I, et al. (2000). mRNA expression of serotonin receptors in cells of the immune tissues of the rat. Brain Behav. Immun. 14: 219-224. http://dx.doi.org/10.1006/brbi.1999.0579   Tan Pei Lin L and Kwek SK (2009). Onset of psoriasis during therapy with fluoxetine. Gen. Hosp. Psychiatry (in press) DOI: 10.1016/j.genhosppsych.2009.08.008. http://dx.doi.org/10.1016/j.genhosppsych.2009.08.008   Tencomnao T and Boonmalert R (2009). Misgenotyping of dopamine receptor D1 gene -48A/G polymorphism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 150B: 447-449. http://dx.doi.org/10.1002/ajmg.b.30814   Tencomnao T, Ketboonlue K, Wongpiyabavorn J, Ronpirin C, et al. (2007). Analysis of autoantibodies to serotonin and serotonin levels in psoriasis. Chin. Med. J. 120: 146.   Turecki G, Briere R, Dewar K, Antonetti T, et al. (1999). Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am. J. Psychiatry 156: 1456-1458.   Warren JT Jr, Peacock ML, Rodriguez LC and Fink JK (1993). An MspI polymorphism in the hyman serotonin receptor gene (HTR2): detection by DGGE and RFLP analysis. Hum. Mol. Genet. 2: 338. http://dx.doi.org/10.1093/hmg/2.3.338   Wongpiyabovorn J, Yooyongsatit S, Ruchusatsawat K, Avihingsanon Y, et al. (2008a). Association of the CTG (-2578/-460/+405) haplotype within the vascular endothelial growth factor gene with early-onset psoriasis. Tissue Antigens 72: 458-463. http://dx.doi.org/10.1111/j.1399-0039.2008.01134.x   Wongpiyabovorn J, Hirankarn N, Ruchusatsawat K, Yooyongsatit S, et al. (2008b). Association of the interleukin-10 distal promoter (-2763A/C) polymorphism with late-onset psoriasis. Clin. Exp. Dermatol. 33: 186-189. http://dx.doi.org/10.1111/j.1365-2230.2007.02628.x   Wu J, Chen F, Zhang X, Li Y, et al. (2009). Association of MIF promoter polymorphisms with psoriasis in a Han population in northeastern China. J. Dermatol. Sci. 53: 212-215. http://dx.doi.org/10.1016/j.jdermsci.2008.11.002   Ying S, Liu XM, Sun YM and Pan SH (2009). Genetic polymorphism c.1438A>G of the 5-HT(2A) receptor is associated with abdominal obesity in Chinese Northern Han population. Mol. Biol. Rep. 36: 91-95. http://dx.doi.org/10.1007/s11033-007-9155-6   Zhang J, Shen Y, He G, Li X, et al. (2008). Lack of association between three serotonin genes and suicidal behavior in Chinese psychiatric patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 32: 467-471. http://dx.doi.org/10.1016/j.pnpbp.2007.09.019
T. Tencomnao and Wongpiyabovorn, J., An investigation of the relationship between serotonin transporter gene promoter polymorphism and psoriasis susceptibility in a Thai population, vol. 9, pp. 2275-2282, 2010.
Amara SG and Pacholczyk T (1991). Sodium-dependent neurotransmitter reuptake systems. Curr. Opin. Neurobiol. 1: 84-90. http://dx.doi.org/10.1016/0959-4388(91)90014-X   Azmitia EC (2001). Modern views on an ancient chemical: serotonin effects on cell proliferation, maturation, and apoptosis. Brain Res. Bull. 56: 413-424. http://dx.doi.org/10.1016/S0361-9230(01)00614-1   Azmitia EC Jr and McEwen BS (1969). Corticosterone regulation of tryptophan hydroxylase in midbrain of the rat. Science 166: 1274-1276. http://dx.doi.org/10.1126/science.166.3910.1274 PMid:5350319   Azmitia EC, Liao B and Chen YS (1993). Increase of tryptophan hydroxylase enzyme protein by dexamethasone in adrenalectomized rat midbrain. J. Neurosci. 13: 5041-5055. PMid:8254360   Barth JH and Baker H (1986). Generalized pustular psoriasis precipitated by trazodone in the treatment of depression. Br. J. Dermatol. 115: 629-630. http://dx.doi.org/10.1111/j.1365-2133.1986.tb05776.x PMid:3790438   Geba GP, Ptak W, Anderson GM, Paliwal V, et al. (1996). Delayed-type hypersensitivity in mast cell-deficient mice: dependence on platelets for expression of contact sensitivity. J. Immunol. 157: 557-565. PMid:8752902   Gelernter J, Kranzler H and Cubells JF (1997). Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African- and European-American and Japanese populations and in alcohol-dependent subjects. Hum. Genet. 101: 243-246. http://dx.doi.org/10.1007/s004390050624 PMid:9402979   Gelernter J, Cubells JF, Kidd JR, Pakstis AJ, et al. (1999). Population studies of polymorphisms of the serotonin transporter protein gene. Am. J. Med. Genet. 88: 61-66. http://dx.doi.org/10.1002/(SICI)1096-8628(19990205)88:1<61::AID-AJMG11>3.0.CO;2-K   Griffiths CE and Richards HL (2001). Psychological influences in psoriasis. Clin. Exp. Dermatol. 26: 338-342. http://dx.doi.org/10.1046/j.1365-2230.2001.00834.x PMid:11422186   Haberstick BC, Smolen A and Hewitt JK (2006). Family-based association test of the 5HTTLPR and aggressive behavior in a general population sample of children. Biol. Psychiatry 59: 836-843. http://dx.doi.org/10.1016/j.biopsych.2005.10.008 PMid:16412987   Heils A, Teufel A, Petri S, Stober G, et al. (1996). Allelic variation of human serotonin transporter gene expression. J. Neurochem. 66: 2621-2624. http://dx.doi.org/10.1046/j.1471-4159.1996.66062621.x PMid:8632190   Huang J, Li G, Xiang J, Yin D, et al. (2004). Immunohistochemical study of serotonin in lesions of psoriasis. Int. J. Dermatol. 43: 408-411. http://dx.doi.org/10.1111/j.1365-4632.2004.02195.x PMid:15186219   Hwu WL, Yang CF, Fann CS, Chen CL, et al. (2005). Mapping of psoriasis to 17q terminus. J. Med. Genet. 42: 152-158. http://dx.doi.org/10.1136/jmg.2004.018564 PMid:15689454 PMCid:1736001   Kasperska-Zajac A, Brzoza Z and Rogala B (2008). Platelet function in cutaneous diseases. Platelets 19: 317-321. http://dx.doi.org/10.1080/09537100802082249 PMid:18791936   Kingo K, Koks S, Silm H and Vasar E (2003). IL-10 promoter polymorphisms influence disease severity and course in psoriasis. Genes Immun. 4: 455-457. http://dx.doi.org/10.1038/sj.gene.6364004 PMid:12944983   Lesch KP, Wolozin BL, Murphy DL and Reiderer P (1993). Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J. Neurochem. 60: 2319-2322. http://dx.doi.org/10.1111/j.1471-4159.1993.tb03522.x PMid:7684072   Lesch KP, Balling U, Gross J, Strauss K, et al. (1994). Organization of the human serotonin transporter gene. J. Neural Transm. Gen. Sect. 95: 157-162. http://dx.doi.org/10.1007/BF01276434   Lesch KP, Bengel D, Heils A, Sabol SZ, et al. (1996). Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274: 1527-1531. http://dx.doi.org/10.1126/science.274.5292.1527 PMid:8929413   Mortensen OV, Thomassen M, Larsen MB, Whittemore SR, et al. (1999). Functional analysis of a novel human serotonin transporter gene promoter in immortalized raphe cells. Brain Res. Mol. Brain Res. 68: 141-148. http://dx.doi.org/10.1016/S0169-328X(99)00083-2   Mössner R, Stiens G, Konig IR, Schmidt D, et al. (2009). Analysis of a functional serotonin transporter promoter polymorphism in psoriasis vulgaris. Arch. Dermatol. Res. 301: 443-447. http://dx.doi.org/10.1007/s00403-008-0909-3 PMid:18979110 PMCid:2701995   Nordlind K, Thorslund K, Lonne-Rahm S, Mohabbati S, et al. (2006). Expression of serotonergic receptors in psoriatic skin. Arch. Dermatol. Res. 298: 99-106. http://dx.doi.org/10.1007/s00403-006-0652-6 PMid:16794822   O'Connell PJ, Wang X, Leon-Ponte M, Griffiths C, et al. (2006). A novel form of immune signaling revealed by transmission of the inflammatory mediator serotonin between dendritic cells and T cells. Blood 107: 1010-1017. http://dx.doi.org/10.1182/blood-2005-07-2903 PMid:16223770 PMCid:1895901   O'Sullivan RL, Lipper G and Lerner EA (1998). The neuro-immuno-cutaneous-endocrine network: relationship of mind and skin. Arch. Dermatol. 134: 1431-1435. http://dx.doi.org/10.1001/archderm.134.11.1431 PMid:9828880   Osborne SF, Stafford L and Orr KG (2002). Paroxetine-associated psoriasis. Am. J. Psychiatry 159: 2113. http://dx.doi.org/10.1176/appi.ajp.159.12.2113 PMid:12450972   Ospina-Duque J, Duque C, Carvajal-Carmona L, Ortiz-Barrientos D, et al. (2000). An association study of bipolar mood disorder (type I) with the 5-HTTLPR serotonin transporter polymorphism in a human population isolate from Colombia. Neurosci. Lett. 292: 199-202. http://dx.doi.org/10.1016/S0304-3940(00)01464-6   Peters BP, Weissman FG and Gill MA (2000). Pathophysiology and treatment of psoriasis. Am. J. Health Syst. Pharm. 57: 645-659. PMid:10768819   Ramamoorthy S, Bauman AL, Moore KR, Han H, et al. (1993). Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc. Natl. Acad. Sci. U. S. A. 90: 2542-2546. http://dx.doi.org/10.1073/pnas.90.6.2542 PMid:7681602 PMCid:46124   Reich A and Szepietowski JC (2007). Mediators of pruritus in psoriasis. Mediators Inflamm. 2007: 64727. http://dx.doi.org/10.1155/2007/64727 PMid:18288273 PMCid:2221678   Ronpirin C, Tencomnao T and Wongpiyabovorn J (2010). Association between the -1438A/G polymorphism of the serotonin 2A receptor gene and late-onset psoriasis in a Thai population. Genet. Mol. Res. 9: 208-214. http://dx.doi.org/10.4238/vol9-1gmr718 PMid:20198576   Settin A, Hassan H, El-Baz R and Hassan T (2009). Association of cytokine gene polymorphisms with psoriasis in cases from the Nile Delta of Egypt. Acta Dermatovenerol. Alp Panonica. Adriat. 18: 105-112. PMid:19784523   Tan Pei LL and Kwek SK (2010). Onset of psoriasis during therapy with fluoxetine. Gen. Hosp. Psychiatry 32: 446.   Tencomnao T, Ketboonlue K, Wongpiyabavorn J, Ronpirin C, et al. (2007). Analysis of autoantibodies to serotonin and serotonin levels in psoriasis. Chin. Med. J. 120 (Suppl 2): P07-P02.   Thorslund K, El-Nour H and Nordlind K (2009). The serotonin transporter protein is expressed in psoriasis, where it may play a role in regulating apoptosis. Arch. Dermatol. Res. 301: 449-457. http://dx.doi.org/10.1007/s00403-009-0933-y PMid:19263059   Tomfohrde J, Silverman A, Barnes R, Fernandez-Vina MA, et al. (1994). Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 264: 1141-1145. http://dx.doi.org/10.1126/science.8178173 PMid:8178173   Tsai SJ, Hong CJ, Yu YW, Lin CH, et al. (2000). Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response. Schizophr. Res. 44: 177-181. http://dx.doi.org/10.1016/S0920-9964(99)00170-X   You JS, Hu SY, Chen B and Zhang HG (2005). Serotonin transporter and tryptophan hydroxylase gene polymorphisms in Chinese patients with generalized anxiety disorder. Psychiatr. Genet. 15: 7-11. http://dx.doi.org/10.1097/00041444-200503000-00002 PMid:15722951
C. Ronpirin, Achariyakul, M., Tencomnao, T., Wongpiyabovorn, J., and Chaicumpa, W., Up-regulation of Id1 in peripheral blood of psoriatic patients, vol. 9, pp. 2239-2247, 2010.
Abrams JR, Kelley SL, Hayes E, Kikuchi T, et al. (2000). Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J. Exp. Med. 192: 681-694. http://dx.doi.org/10.1084/jem.192.5.681 PMid:10974034 PMCid:2193278   Ackerman AB (1978). Psoriasis. In: Histologic Diagnosis of Inflammatory Skin Diseases (Ackerman AB, ed.). Lea and Febiger, Philadelphia, 251-256.   Austin LM, Ozawa M, Kikuchi T, Walters IB, et al. (1999). The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. 113: 752-759. http://dx.doi.org/10.1046/j.1523-1747.1999.00749.x PMid:10571730   Bata-Csorgo Z, Hammerberg C, Voorhees JJ and Cooper KD (1995a). Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia. J. Invest. Dermatol. 105: 89S-94S. http://dx.doi.org/10.1038/jid.1995.18 PMid:7616005   Bata-Csorgo Z, Hammerberg C, Voorhees JJ and Cooper KD (1995b). Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J. Clin. Invest. 95: 317-327. http://dx.doi.org/10.1172/JCI117659 PMid:7529261 PMCid:295434   Bjorntorp E, Parsa R, Thornemo M, Wennberg AM, et al. (2003). The helix-loop-helix transcription factor Id1 is highly expressed in psoriatic involved skin. Acta Derm. Venereol. 83: 403-409. http://dx.doi.org/10.1080/00015550310015806 PMid:14690332   Böhm I (2006). Quantification of absolute peripheral white blood cells and their subsets in patients with lupus erythematosus: comparison with other inflammatory diseases with and without autoimmune background. Biomed. Pharmacother. 60: 92-95. http://dx.doi.org/10.1016/j.biopha.2005.06.007 PMid:16256301   Bonifati C, Carducci M, Cordiali FP, Trento E, et al. (1994). Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients - relationships with disease severity. Clin. Exp. Dermatol. 19: 383-387. http://dx.doi.org/10.1111/j.1365-2230.1994.tb02687.x PMid:7955493   Ettehadi P, Greaves MW, Wallach D, Aderka D, et al. (1994). Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin. Exp. Immunol. 96: 146-151. http://dx.doi.org/10.1111/j.1365-2249.1994.tb06244.x PMid:8149659 PMCid:1534536   Friedrich M, Krammig S, Henze M, Docke WD, et al. (2000). Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch. Dermatol. Res. 292: 519-521. http://dx.doi.org/10.1007/s004030000167 PMid:11142774   Gottlieb AB, Lebwohl M, Shirin S, Sherr A, et al. (2000). Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J. Am. Acad. Dermatol. 43: 595-604. http://dx.doi.org/10.1067/mjd.2000.107945 PMid:11004613   Gottlieb AB, Masud S, Ramamurthi R, Abdulghani A, et al. (2003). Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J. Am. Acad. Dermatol. 48: 68-75. http://dx.doi.org/10.1067/mjd.2003.10 PMid:12522373   Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, et al. (1995). Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. 1: 442-447. http://dx.doi.org/10.1038/nm0595-442 PMid:7585092   Henseler T (1998). Genetics of psoriasis. Arch. Dermatol. Res. 290: 463-476. http://dx.doi.org/10.1007/s004030050338 PMid:9808339   Hu LH, Chen FH, Li YR and Wang L (2004). Real-time determination of human telomerase reverse transcriptase mRNA in gastric cancer. World J. Gastroenterol. 10: 3514-3517. PMid:15526376   Ishiguro A, Spirin KS, Shiohara M, Tobler A, et al. (1996). Id2 expression increases with differentiation of human myeloid cells. Blood 87: 5225-5231. PMid:8652837   Jeffes EW III, McCullough JL, Pittelkow MR, McCormick A, et al. (1995). Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J. Invest. Dermatol. 104: 183-188. http://dx.doi.org/10.1111/1523-1747.ep12612745 PMid:7829873   Ketboonlue K (2007). Detection of Serotonin and Development of Laboratory Technique for Detecting Autoantibodies to Serotonin in the Psoriatic Patients' Blood. Master's thesis, Chulalongkorn University, Bangkok.   Krueger JG, Walters IB, Miyazawa M, Gilleaudeau P, et al. (2000). Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J. Am. Acad. Dermatol. 43: 448-458. http://dx.doi.org/10.1067/mjd.2000.106515 PMid:10954656   Kupper TS (2003). Immunologic targets in psoriasis. N. Engl. J. Med. 349: 1987-1990. http://dx.doi.org/10.1056/NEJMp038164 PMid:14627782   Lowes MA, Bowcock AM and Krueger JG (2007). Pathogenesis and therapy of psoriasis. Nature 445: 866-873. http://dx.doi.org/10.1038/nature05663 PMid:17314973   Mark EB, Jonsson M, Asp J, Wennberg AM, et al. (2006). Expression of genes involved in the regulation of p16 in psoriatic involved skin. Arch. Dermatol. Res. 297: 459-467. http://dx.doi.org/10.1007/s00403-006-0649-1 PMid:16552541   Marsland AM and Griffiths CE (2002). The macrolide immunosuppressants in dermatology: mechanisms of action. Eur. J. Dermatol. 12: 618-622. PMid:12459545   Nair RP, Duffin KC, Helms C, Ding J, et al. (2009). Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat. Genet. 41: 199-204. http://dx.doi.org/10.1038/ng.311 PMid:19169254 PMCid:2745122   Naldi L (2010). Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passe? Facts and controversies. Clin. Dermatol. 28: 67-72. http://dx.doi.org/10.1016/j.clindermatol.2009.03.001 PMid:20082954   Ockenfels HM, Nussbaum G, Schultewolter T, Mertins K, et al. (1995). Tyrosine phosphorylation in psoriatic T cells is modulated by drugs that induce or improve psoriasis. Dermatology 191: 217-225. http://dx.doi.org/10.1159/000246549 PMid:8534940   Ozawa A, Sugai J, Ohkido M, Ohtsuki M, et al. (1999). Cyclosporin in psoriasis: continuous monotherapy versus intermittent long-term therapy. Eur. J. Dermatol. 9: 218-223. PMid:10210789   Prinz JC, Gross B, Vollmer S, Trommler P, et al. (1994). T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. Eur. J. Immunol. 24: 593-598. http://dx.doi.org/10.1002/eji.1830240315 PMid:8125129   Rivera R and Murre C (2001). The regulation and function of the Id proteins in lymphocyte development. Oncogene 20: 8308-8316. http://dx.doi.org/10.1038/sj.onc.1205091 PMid:11840323   Rocha-Pereira P, Santos-Silva A, Rebelo I, Figneiredo A, et al. (2004). Erythrocyte damage in mild and severe psoriasis. Br. J. Dermatol. 150: 232-244. http://dx.doi.org/10.1111/j.1365-2133.2004.05801.x PMid:14996093   Ronpirin C and Tencomnao T (2010). Psoriasis: A review of the role of serotonergic system. Afr. J. Biotechnol. 9: 1528- 1534.   Sakurai D, Yamaguchi A, Tsuchiya N, Yamamoto K, et al. (2001). Expression of ID family genes in the synovia from patients with rheumatoid arthritis. Biochem. Biophys. Res. Commun. 284: 436-442. http://dx.doi.org/10.1006/bbrc.2001.4974 PMid:11394898   Schön MP and Boehncke WH (2005). Psoriasis. N. Engl. J. Med. 352: 1899-1912. http://dx.doi.org/10.1056/NEJMra041320 PMid:15872205   Suh HC, Leeanansaksiri W, Ji M, Klarmann KD, et al. (2008). Id1 immortalizes hematopoietic progenitors in vitro and promotes a myeloproliferative disease in vivo. Oncogene 27: 5612-5623. http://dx.doi.org/10.1038/onc.2008.175 PMid:18542061 PMCid:3073486   Szabo SK, Hammerberg C, Yoshida Y, Bata-Csorgo Z, et al. (1998). Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets. J. Invest. Dermatol. 111: 1072- 1078. http://dx.doi.org/10.1046/j.1523-1747.1998.00419.x PMid:9856819   Tam WF, Gu TL, Chen J, Lee BH, et al. (2008). Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. Blood 112: 1981-1992. http://dx.doi.org/10.1182/blood-2007-07-103010 PMid:18559972 PMCid:2518899   Vallat VP, Gilleaudeau P, Battat L, Wolfe J, et al. (1994). PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J. Exp. Med. 180: 283-296. http://dx.doi.org/10.1084/jem.180.1.283 PMid:7516410   Vollmer S, Menssen A, Trommler P, Schendel D, et al. (1994). T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur. J. Immunol. 24: 2377-2382. http://dx.doi.org/10.1002/eji.1830241018 PMid:7925564   Wong YC, Wang X and Ling MT (2004). Id-1 expression and cell survival. Apoptosis 9: 279-289. http://dx.doi.org/10.1023/B:APPT.0000025804.25396.79 PMid:15258459   Yang Y, Liou HC and Sun XH (2006). Id1 potentiates NF-kappaB activation upon T cell receptor signaling. J. Biol. Chem. 281: 34989-34996. http://dx.doi.org/10.1074/jbc.M608078200 PMid:17012234